|
|
Found results for
 patents
1.
|
POLYMORPHS OF A PHOSPHATE SALT OF QUINUCLIDIN-4-YLMETHYL 4-METHYL-1H-INDOLE-3-CARBOXYLATE AND USES THEREOF
| Application Number |
US2017012619 |
| Publication Number |
2017/120532 |
| Status |
In Force |
| Filing Date |
2017-01-06 |
| Publication Date |
2017-07-13 |
| Owner |
ALPHARMAGEN, LLC (USA)
|
| Inventor |
- Ng, John, Sau-Hoi
- Ng, Raymond
|
Abstract
Provided is a phosphate salt of quinuclidin-4-ylmethyl 4-methyl-1H-indole-3- carboxylate, in particular polymorphic Form A, a process for their preparation of said salt, in particular in polymorphic Form A, and a pharmaceutical composition containing said salt.
IPC Classes ?
- C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
|
2.
|
ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF
| Application Number |
US2016020984 |
| Publication Number |
2016/144792 |
| Status |
In Force |
| Filing Date |
2016-03-04 |
| Publication Date |
2016-09-15 |
| Owner |
ALPHARMAGEN, LLC (USA)
|
| Inventor |
- Putman, David, G.
- Dasse, Olivier
- Hogenkamp, Derk
|
Abstract
The present application is related to compounds represented by Formula I, which are novel positive allosteric modulators of α7 nAChRs. The application also discloses the treatment of disorders that are responsive to enhancement of acetylcholine action on α7 nAChRs in a mammal by administering an effective amount of a compound of Formula I.
|
3.
|
ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF
| Application Number |
US2016020994 |
| Publication Number |
2016/144797 |
| Status |
In Force |
| Filing Date |
2016-03-04 |
| Publication Date |
2016-09-15 |
| Owner |
ALPHARMAGEN, LLC (USA)
|
| Inventor |
- Putman, David, G.
- Dasse, Olivier
- Hogenkamp, Derk
- Ng, Raymond
|
Abstract
The present application is related to compounds represented by Formula I, which are novel positive allosteric modulators of α7 nAChRs. The application also discloses the treatment of disorders that are responsive to enhancement of acetylcholine action on α7 nAChRs in a mammal by administering an effective amount of a compound of Formula I.
|
4.
|
QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7 -NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY
| Application Number |
US2015039560 |
| Publication Number |
2016/007630 |
| Status |
In Force |
| Filing Date |
2015-07-08 |
| Publication Date |
2016-01-14 |
| Owner |
ALPHARMAGEN, LLC (USA)
|
| Inventor |
- Bilcer, Geoffrey, M.
- Ng, Raymond
|
Abstract
Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating α7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds.
IPC Classes ?
- C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- C07D 471/08 - Bridged systems
- C07D 209/04 - IndolesHydrogenated indoles
- A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
|
5.
|
Quinuclidines for modulating alpha 7 activity
| Application Number |
14794497 |
| Grant Number |
09434724 |
| Status |
In Force |
| Filing Date |
2015-07-08 |
| First Publication Date |
2016-01-14 |
| Grant Date |
2016-09-06 |
| Owner |
ALPHARMAGEN, LLC (USA)
|
| Inventor |
- Bilcer, Geoffrey M.
- Ng, Raymond
|
Abstract
Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating α7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds.
IPC Classes ?
- C07D 453/00 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D 209/04 - IndolesHydrogenated indoles
- A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
|
|
